4-1BB binding molecules
View Patent ↗The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
1. An isolated antibody, or antigen-binding portion thereof, wherein said antibody, or antigen-binding portion comprises:
(a) the H-CDR1 as set forth in SEQ ID NO:29;
(b) the H-CDR2 as set forth in SEQ ID NO:30;
(c) the H-CDR3 as set forth in SEQ ID NO:31;
(d) the L-CDR1 as set forth in SEQ ID NO:34;
(e) the L-CDR2 as set forth in SEQ ID NO:35; and
(f) the L-CDR3 as set forth in SEQ ID NO:36.
2. The antibody, or antigen-binding portion according to claim 1 wherein said antibody, or antigen-binding portion comprises the V H region amino acid sequence as set forth in SEQ ID NO:43.
3. The antibody, or antigen-binding portion according to claim 1 wherein said antibody, or antigen-binding portion comprises the V L region amino acid sequence as set forth in SEQ ID NO:45.
4. The antibody, or antigen-binding portion according to claim 1 , comprising the V H region amino acid sequence as set forth in SEQ ID NO:43 and the V L region amino acid sequence as set forth in SEQ ID NO:45.
5. The isolated antibody according to claim 1 , which is an IgG2.
6. A pharmaceutical composition comprising an antibody, or antigen-binding portion thereof, according to claim 1 and a pharmaceutically acceptable carrier.
7. An isolated antibody, wherein said antibody comprises the heavy chain amino acid sequence as set forth in SEQ ID NO:44 and further comprises the light chain amino acid sequence as set forth in SEQ ID NO:46, with the proviso that the C-terminal lysine residue of SEQ ID NO:44 is optionally absent.